1
|
Abstract
PURPOSE OF REVIEW The long-term management goals of the inflammatory airway diseases asthma and chronic obstructive pulmonary disease (COPD) are similar and focus on symptom control and reduction of exacerbation frequency and severity. Treatable traits have recently been postulated as a management concept which complements the traditional diagnostic labels 'asthma' and 'COPD', thereby focusing on therapy targeted to a patients' individual disease-associated characteristics. Exhaled volatile organic compounds (VOCs) may be utilized as noninvasive biomarker for disease activity or manifestation in asthma and COPD. In this review, we provide an overview of the current achievements concerning exhaled breath analysis in the field of uncontrolled chronic airways diseases. RECENT FINDINGS Monitoring of (airway) inflammation and identification of (molecular) phenotypic characteristics in asthma and COPD through exhaled VOC analysis by either mass spectrometry (MS) based or sensor-driven electronic nose technology (eNose) seems to be feasible, however pending confirmation could hamper the valorization of breathomics into clinical tests. SUMMARY Exhaled VOC analysis and the management of asthma and COPD through the concept of pulmonary treatable traits are an interesting match. To develop exhaled breath analysis into an added value for pulmonary treatable traits, multicentre studies are required following international standards for study populations, sampling methods and analytical strategies enabling external validation.
Collapse
|
2
|
Mattes WB, Goodsaid F. Regulatory landscapes for biomarkers and diagnostic tests: Qualification, approval, and role in clinical practice. Exp Biol Med (Maywood) 2017; 243:256-261. [PMID: 29110507 DOI: 10.1177/1535370217739629] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
While the term 'biomarker' is relatively new, the concept is millennia old. However, with the introduction of new technologies to discover potential biomarkers comes the need to assess their utility and veracity for any given use. This is particularly true for the use of biomarkers to support regulatory decisions in medical product development. Hence the US Food and Drug Administration has developed processes for the qualification of biomarkers and other medical product development tools, processes that are underscored by recent legislation (i.e. the 21st Century Cures Act). In addition to these qualification processes, diagnostic tests that measure a biomarker may follow a process for regulatory decision through the processes that evaluate companion diagnostics. This mini-review provides an overview of these processes and their role in pharmaceutical development and clinical use. Impact statement This work summarizes very recent developments in the US FDA's biomarker qualification program. Furthermore, it contrasts biomarker qualification with companion diagnostic evaluation. As such, it will be highly informative for researches considering taking a biomarker discovery farther along the road to validation.
Collapse
Affiliation(s)
- William B Mattes
- 1 National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA
| | | |
Collapse
|
3
|
Abstract
Clinical pharmacologic research plays a vital role in cancer drug development. In recent years, biomarker studies have become integral to this process, specifically the use of pharmacologic biomarkers in the development of targeted therapies and their translation to clinical practice. In this overview, we discuss the validation of pharmacodynamics (PD) biomarkers and highlight the circulating tumor DNA as a promising cancer biomarker to illustrate how PD biomarkers can be powerful tools for guiding treatment strategies. We provide insights into PD biomarker approaches for future development of novel therapies and their role in cancer medicine. See all articles in this CCR focus section, "Progress in pharmacodynamic endpoints."
Collapse
Affiliation(s)
- William Douglas Figg
- Authors' Affiliations: Clinical Pharmacology Program, Office of the Clinical Director, Molecular Pharmacology Section and Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; and Northern Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom
| | - David R Newell
- Authors' Affiliations: Clinical Pharmacology Program, Office of the Clinical Director, Molecular Pharmacology Section and Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; and Northern Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom
| |
Collapse
|
4
|
Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Prog Neurobiol 2014; 122:45-72. [PMID: 25173695 DOI: 10.1016/j.pneurobio.2014.08.002] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2014] [Revised: 08/11/2014] [Accepted: 08/19/2014] [Indexed: 02/07/2023]
Abstract
Major psychiatric disorders such as schizophrenia, major depressive and bipolar disorders are severe, chronic and debilitating, and are associated with high disease burden and healthcare costs. Currently, diagnoses of these disorders rely on interview-based assessments of subjective self-reported symptoms. Early diagnosis is difficult, misdiagnosis is a frequent occurrence and there are no objective tests that aid in the prediction of individual responses to treatment. Consequently, validated biomarkers are urgently needed to help address these unmet clinical needs. Historically, psychiatric disorders are viewed as brain disorders and consequently only a few researchers have as yet evaluated systemic changes in psychiatric patients. However, promising research has begun to challenge this concept and there is an increasing awareness that disease-related changes can be traced in the peripheral system which may even be involved in the precipitation of disease onset and course. Converging evidence from molecular profiling analysis of blood serum/plasma have revealed robust molecular changes in psychiatric patients, suggesting that these disorders may be detectable in other systems of the body such as the circulating blood. In this review, we discuss the current clinical needs in psychiatry, highlight the importance of biomarkers in the field, and review a representative selection of biomarker studies to highlight opportunities for the implementation of personalized medicine approaches in the field of psychiatry. It is anticipated that the implementation of validated biomarker tests will not only improve the diagnosis and more effective treatment of psychiatric patients, but also improve prognosis and disease outcome.
Collapse
|
5
|
|
6
|
Guest PC, Chan MK, Gottschalk MG, Bahn S. The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients. Biomark Med 2014; 8:15-27. [DOI: 10.2217/bmm.13.83] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Schizophrenia is characterized by a wide spectrum of clinical manifestations, including strong effects on mood and behavior. Patients can also suffer from serious comorbidities including immune system or metabolic abnormalities. Recent advances using proteomic profiling approaches have increased our understanding of these molecular effects and have laid the groundwork for unraveling the heterogeneity of this broadly defined disease. These findings could lead to improved diagnosis and stratification of patients through identification of biochemically different disease subtypes and personalized medicine approaches. The inclusion of molecular signatures in psychiatry will be an important leap forward in providing more effective treatment of patients suffering from this debilitating disorder.
Collapse
Affiliation(s)
- Paul C Guest
- Department of Chemical Engineering & Biotechnology, University of Cambridge, Cambridge, UK
| | - Man K Chan
- Department of Chemical Engineering & Biotechnology, University of Cambridge, Cambridge, UK
| | - Michael G Gottschalk
- Department of Chemical Engineering & Biotechnology, University of Cambridge, Cambridge, UK
| | - Sabine Bahn
- Department of Neuroscience, Erasmus Medical Centre, Rotterdam, The Netherlands
| |
Collapse
|
7
|
Anderson D, Kodukula K. Biomarkers in pharmacology and drug discovery. Biochem Pharmacol 2014; 87:172-88. [DOI: 10.1016/j.bcp.2013.08.026] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Accepted: 08/19/2013] [Indexed: 12/21/2022]
|
8
|
Campion S, Aubrecht J, Boekelheide K, Brewster DW, Vaidya VS, Anderson L, Burt D, Dere E, Hwang K, Pacheco S, Saikumar J, Schomaker S, Sigman M, Goodsaid F. The current status of biomarkers for predicting toxicity. Expert Opin Drug Metab Toxicol 2013; 9:1391-408. [PMID: 23961847 PMCID: PMC3870154 DOI: 10.1517/17425255.2013.827170] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
INTRODUCTION There are significant rates of attrition in drug development. A number of compounds fail to progress past preclinical development due to limited tools that accurately monitor toxicity in preclinical studies and in the clinic. Research has focused on improving tools for the detection of organ-specific toxicity through the identification and characterization of biomarkers of toxicity. AREAS COVERED This article reviews what we know about emerging biomarkers in toxicology, with a focus on the 2012 Northeast Society of Toxicology meeting titled 'Translational Biomarkers in Toxicology.' The areas covered in this meeting are summarized and include biomarkers of testicular injury and dysfunction, emerging biomarkers of kidney injury and translation of emerging biomarkers from preclinical species to human populations. The authors also provide a discussion about the biomarker qualification process and possible improvements to this process. EXPERT OPINION There is currently a gap between the scientific work in the development and qualification of novel biomarkers for nonclinical drug safety assessment and how these biomarkers are actually used in drug safety assessment. A clear and efficient path to regulatory acceptance is needed so that breakthroughs in the biomarker toolkit for nonclinical drug safety assessment can be utilized to aid in the drug development process.
Collapse
Affiliation(s)
- Sarah Campion
- Principal Scientist, Drug Safety Research and Development, Pfizer, Inc., Eastern Point Road, MS 8274 1260, Groton, CT 06340, USA
| | - Jiri Aubrecht
- Senior Director, Drug Safety Research and Development, Pfizer, Inc., Eastern Point Road, MS 8274-1424, Groton, CT 06340, USA
| | - Kim Boekelheide
- Professor of Laboratory Medicine, Brown University, Department of Pathology and Laboratory Medicine, Providence, RI 02912, USA
| | - David W Brewster
- Vice-President, Global Head Drug Safety Evaluation, Vertex Pharmaceuticals, Inc., 130 Waverly Street, Cambridge, MA 02139, USA
| | - Vishal S Vaidya
- Assistant Professor of Medicine and Environmental Health, Harvard Institutes of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Harvard School of Public Health, Renal Division, Department of Environmental Health, Rm 510, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
| | - Linnea Anderson
- Graduate Student, Brown University, Department of Pathology and Laboratory Medicine, Providence, RI 02912, USA
| | - Deborah Burt
- Scientist, Drug Safety Research and Development, Pfizer, Inc., Eastern Point Road, MS 8274- 1234, Groton, CT 06340, USA
| | - Edward Dere
- Postdoctoral Associate, Rhode Island Hospital, Division of Urology, Providence, RI 02903, USA
| | - Kathleen Hwang
- Assistant Professor, Rhode Island Hospital, Division of Urology, Providence, RI 02903, USA
| | - Sara Pacheco
- Graduate Student, Brown University, Department of Pathology and Laboratory Medicine, Providence, RI 02912, USA
| | - Janani Saikumar
- Brigham and Women’s Hospital, Harvard Institutes of Medicine, Harvard Medical School, Renal Division, Department of Medicine, Rm 510, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
| | - Shelli Schomaker
- Principal Scientist, Drug Safety Research and Development, Pfizer, Inc., Eastern Point Road, MS 8274-1227, Groton, CT 06340, USA
| | - Mark Sigman
- Chief of Urology, Rhode Island Hospital and The Miriam Hospital, Division of Urology, Providence, RI 02903, USA
| | - Federico Goodsaid
- Vice President, Strategic Regulatory Intelligence, Vertex Pharmaceuticals, Inc., 1050 K Street NW, Suite 1125, Washington, DC 20016, USA
| |
Collapse
|
9
|
Staedtler F, Hartmann N, Letzkus M, Bongiovanni S, Scherer A, Marc P, Johnson KJ, Schumacher MM. Robust and tissue-independent gender-specific transcript biomarkers. Biomarkers 2013; 18:436-45. [PMID: 23829492 DOI: 10.3109/1354750x.2013.811538] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
CONTEXT Correct gender assignment in humans at the molecular level is crucial in many scientific disciplines and applied areas. MATERIALS AND METHODS Candidate gender markers were identified through supervised statistical analysis of genome wide microarray expression data from human blood samples (N = 123, 58 female, 65 male) as a training set. The potential of the markers to predict undisclosed tissue donor gender was tested on microarray data from 13 healthy and 11 cancerous human tissue collections (internal) and external datasets from samples of varying tissue origin. The abundance of some genes in the marker panel was quantified by RT-PCR as alternative analytical technology. RESULTS We identified and qualified predictive, gender-specific transcript markers based on a set of five genes (RPS4Y1, EIF1AY, DDX3Y, KDM5D and XIST). CONCLUSION Gene expression marker panels can be used as a robust tissue- and platform-independent predictive approach for gender determination.
Collapse
Affiliation(s)
- Frank Staedtler
- Novartis Institutes for BioMedical Research (NIBR), Biomarker Development, Basel, Switzerland.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Ding W, Qiu P, Liu YH, Feng W. Current Omics Technologies in Biomarker Discovery. Bioinformatics 2013. [DOI: 10.4018/978-1-4666-3604-0.ch027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Biomarkers are playing an increasingly important role in drug discovery and development and can be applied for many purposes, including disease mechanism study, diagnosis, prognosis, staging, and treatment selection. Advances in high-throughput “omics” technologies, including genomics, transcriptomics, proteomics and metabolomics, significantly accelerate the pace of biomarker discovery. Comprehensive molecular profiling using these “omics” technology has become a field of intensive research aiming at identifying biomarkers relevant for improved diagnostics and therapeutics. Although each “omics” technology plays important roles in biomarker research, different “omics” platforms have different strengths and limitations. This chapter aims to give an overview of these “omics” technologies and their current application in the biomarker discovery.
Collapse
|
11
|
Guest PC, Martins-de-Souza D, Schwarz E, Rahmoune H, Alsaif M, Tomasik J, Turck CW, Bahn S. Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Med 2013; 5:25. [PMID: 23531373 PMCID: PMC3706977 DOI: 10.1186/gm429] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Schizophrenia is a heterogeneous psychiatric disorder characterized by an array of clinical manifestations. Although the best known manifestations include serious effects on mood and behavior, patients can also display co-morbidities, including immune system or metabolic abnormalities. Thorough characterization of these conditions using proteomic profiling methods has increased our knowledge of these molecular differences and has helped to unravel the complexity and heterogeneity of this debilitating condition. This could lead to patient stratification through characterization of biochemically different subtypes of the disease. In addition, proteomic methods have recently been used for molecular characterization of the mechanism of action of antipsychotic medications in both preclinical models and patients. This has resulted in identification of molecular panels that show some promise for prediction of response or for monitoring treatment outcome. This review describes how proteomic profiling methods can impact the future of schizophrenia diagnosis and therapeutics, and facilitate personalized medicine approaches for more effective treatment management of schizophrenia patients.
Collapse
Affiliation(s)
- Paul C Guest
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT, UK
| | - Daniel Martins-de-Souza
- Max Planck Institute of Psychiatry, Proteomics and Biomarkers, Kraepelinstr. 2-10 80804, Munich, Germany ; Department of Psychiatry, Ludwig-Maximilians-University (LMU), Nussbaumstr. 7, 80336, Munich, Germany ; Laboratório de Neurociências (LIM-27), Instituto de Psiquiatria, Faculdade de Medicina, Universidade de São Paulo, CP 8091 05403-010 São Paulo - SP - Brasil
| | - Emanuel Schwarz
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT, UK
| | - Hassan Rahmoune
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT, UK
| | - Murtada Alsaif
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT, UK
| | - Jakub Tomasik
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT, UK
| | - Christoph W Turck
- Max Planck Institute of Psychiatry, Proteomics and Biomarkers, Kraepelinstr. 2-10 80804, Munich, Germany
| | - Sabine Bahn
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT, UK ; Department of Neuroscience, Erasmus Medical Centre, NL-3000 CA Rotterdam, The Netherlands
| |
Collapse
|
12
|
Guest PC, Gottschalk MG, Bahn S. Proteomics: improving biomarker translation to modern medicine? Genome Med 2013; 5:17. [PMID: 23445684 PMCID: PMC3706758 DOI: 10.1186/gm421] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Affiliation(s)
- Paul C Guest
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK
| | - Michael G Gottschalk
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK
| | - Sabine Bahn
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK ; Department of Neuroscience, Erasmus Medical Centre, Rotterdam, The Netherlands
| |
Collapse
|
13
|
Bahn S, Schwarz E, Harris LW, Martins-de-Souza D, Rahmoune H, Guest PC. Testes sanguíneos de biomarcadores para diagnóstico e tratamento de desordens mentais: foco em esquizofrenia. ACTA ACUST UNITED AC 2012. [DOI: 10.1590/s0101-60832012005000005] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A descoberta e a aplicação clínica de biomarcadores para desordens mentais são confrontadas com muitos desafios. Em geral, os atuais métodos de descoberta e validação de biomarcadores não produziram os resultados que foram inicialmente aguardados depois da finalização do Projeto Genoma Humano. Isso se deve principalmente à falta de processos padronizados conectando a descoberta de marcadores com tecnologias para a validação e a tradução para uma plataforma que ofereça precisão e fácil uso em clínica. Como consequência, a maior parte dos psiquiatras e praticantes em geral são relutantes em aceitar que testes de biomarcadores pode suplementar ou substituir os métodos de diagnóstico utilizados baseados em entrevista. Apesar disso, agências regulatórias concordam agora que melhoras nos correntes métodos são essenciais. Além disso, essas agências estipularam que biomarcadores são importantes para o desenvolvimento de futuras drogas e iniciaram esforços no sentido de modernizar métodos e técnicas para suportar esses esforços. Aqui revisamos os desafios encontrados por essa tentativa do ponto de vista de psiquiatras, praticantes em geral, agências reguladoras e cientistas de biomarcadores. Também descrevemos o desenvolvimento de um novo teste sanguíneo molecular para esquizofrenia como um primeiro passo a esse objetivo.
Collapse
Affiliation(s)
- Sabine Bahn
- Universidade de Cambridge; Centro Médico Erasmus, Holanda
| | | | | | | | | | | |
Collapse
|
14
|
Mass Spectrometry-Based Multiplexing for the Analysis of Biomarkers in Drug Development and Clinical Diagnostics- How Much is too Much? Microchem J 2012; 105:32-38. [PMID: 23645936 DOI: 10.1016/j.microc.2012.02.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Biomarkers, or more specifically molecular markers, can detect biochemical changes associated with disease processes and drug effects before histopathological and pathophysiological changes occur. Multiplexing technologies such as high-performance liquid chromatography/mass spectrometry (LC-MS) allow for the measurement of molecular marker patterns that confer significantly more information than the measurement of a single parameter alone. The use of multiplexing assays for drug development, and as diagnostic tools, is attractive but will require regulatory review and approval and thus requires validation following regulatory guidances. Multiplexing assays always constitute a compromise. The number of analytes that can reasonably be included in a mass spectrometry-based multiplexing assay depend on the physico-chemical properties of the analytes and their integration into a single assay in terms of extraction, HPLC separation, ionization conditions and mass spectrometry detection. Another aspect includes biomedical considerations such as the differences in physiological concentrations of analytes, the required concentration range, and how much variability is acceptable before the clinical utility of a marker is negatively affected. Regulatory considerations include validation and quality control during sample analysis. Current bioanalytical regulatory guidelines have mostly been developed for single drug compounds and are not always adequate for multiplexing molecular marker assays that often quantify endogenous compounds. Specific guidances for multiplexing assays should be developed. Even if it is possible to integrate a wide variety and large number of analytes into a multiplexing assay, it should always be taken into consideration that a set of shorter, more specialized assays, may offer a more manageable and efficient alternative.
Collapse
|
15
|
Bahn S, Schwarz E. Serumbiomarker für psychiatrische Erkrankungen. DER NERVENARZT 2011; 82:1395-6, 1398, 1400 passim. [DOI: 10.1007/s00115-011-3346-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
16
|
Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegård D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011; 19:515-42. [PMID: 21396468 PMCID: PMC3568396 DOI: 10.1016/j.joca.2010.08.019] [Citation(s) in RCA: 220] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2010] [Revised: 08/21/2010] [Accepted: 08/28/2010] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Osteoarthritis (OA) is a chronic and slowly progressive disease for which biomarkers may be able to provide a more rapid indication of therapeutic responses to therapy than is currently available; this could accelerate and facilitate OA drug discovery and development programs. The goal of this document is to provide a summary and guide to the application of in vitro (biochemical and other soluble) biomarkers in the development of drugs for OA and to outline and stimulate a research agenda that will further this goal. METHODS The Biomarkers Working Group representing experts in the field of OA biomarker research from both academia and industry developed this consensus document between 2007 and 2009 at the behest of the Osteoarthritis Research Society International Federal Drug Administration initiative (OARSI FDA initiative). RESULTS This document summarizes definitions and classification systems for biomarkers, the current outcome measures used in OA clinical trials, applications and potential utility of biomarkers for development of OA therapeutics, the current state of qualification of OA-related biomarkers, pathways for biomarker qualification, critical needs to advance the use of biomarkers for drug development, recommendations regarding practices and clinical trials, and a research agenda to advance the science of OA-related biomarkers. CONCLUSIONS Although many OA-related biomarkers are currently available they exist in various states of qualification and validation. The biomarkers that are likely to have the earliest beneficial impact on clinical trials fall into two general categories, those that will allow targeting of subjects most likely to either respond and/or progress (prognostic value) within a reasonable and manageable time frame for a clinical study (for instance within 1-2 years for an OA trial), and those that provide early feedback for preclinical decision-making and for trial organizers that a drug is having the desired biochemical effect. As in vitro biomarkers are increasingly investigated in the context of specific drug treatments, advances in the field can be expected that will lead to rapid expansion of the list of available biomarkers with increasing understanding of the molecular processes that they represent.
Collapse
Affiliation(s)
- V B Kraus
- Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC, Aerts HJWL, Bendriem B, Bendtsen C, Boellaard R, Boone JM, Cole PE, Conklin JJ, Dorfman GS, Douglas PS, Eidsaunet W, Elsinger C, Frank RA, Gatsonis C, Giger ML, Gupta SN, Gustafson D, Hoekstra OS, Jackson EF, Karam L, Kelloff GJ, Kinahan PE, McLennan G, Miller CG, Mozley PD, Muller KE, Patt R, Raunig D, Rosen M, Rupani H, Schwartz LH, Siegel BA, Sorensen AG, Wahl RL, Waterton JC, Wolf W, Zahlmann G, Zimmerman B. Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology 2011; 259:875-84. [PMID: 21325035 DOI: 10.1148/radiol.10100800] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
UNLABELLED Quantitative imaging biomarkers could speed the development of new treatments for unmet medical needs and improve routine clinical care. However, it is not clear how the various regulatory and nonregulatory (eg, reimbursement) processes (often referred to as pathways) relate, nor is it clear which data need to be collected to support these different pathways most efficiently, given the time- and cost-intensive nature of doing so. The purpose of this article is to describe current thinking regarding these pathways emerging from diverse stakeholders interested and active in the definition, validation, and qualification of quantitative imaging biomarkers and to propose processes to facilitate the development and use of quantitative imaging biomarkers. A flexible framework is described that may be adapted for each imaging application, providing mechanisms that can be used to develop, assess, and evaluate relevant biomarkers. From this framework, processes can be mapped that would be applicable to both imaging product development and to quantitative imaging biomarker development aimed at increasing the effectiveness and availability of quantitative imaging. SUPPLEMENTAL MATERIAL http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.10100800/-/DC1.
Collapse
|
18
|
Wong EHF, Fox JC, Ng MYM, Lee CM. Toward personalized medicine in the neuropsychiatric field. INTERNATIONAL REVIEW OF NEUROBIOLOGY 2011; 101:329-49. [PMID: 22050858 DOI: 10.1016/b978-0-12-387718-5.00013-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
There are great expectations for the personalized medicine approach to address the therapeutic needs of patients in the twenty-first century. Advances in human genome science and molecular innovations in neuroscience have encouraged the pharmaceutical industry to focus beyond broad spectrum population therapeutics--the driving force behind the "blockbuster" product concept--to personalized medicine. For central nervous system (CNS) therapeutics, repeated failures in converting scientific discoveries to clinical trial successes and regulatory approvals have precipitated a drug pipeline crisis and eroded confidence in the industry. This chapter describes how innovations in genomics and translational medicine can impact the future of neuropsychiatry and deconvolute the complexity of psychiatric diseases from symptoms biology. A targeted and consistent investment is needed to restore confidence in translating science into clinical success.
Collapse
Affiliation(s)
- Erik H F Wong
- AstraZeneca Pharmaceuticals, External Science, CNS-Pain Innovative Medicine Unit, Wilmington, Delaware, USA
| | | | | | | |
Collapse
|
19
|
Bahn S, Noll R, Barnes A, Schwarz E, Guest PC. Challenges of introducing new biomarker products for neuropsychiatric disorders into the market. INTERNATIONAL REVIEW OF NEUROBIOLOGY 2011; 101:299-327. [PMID: 22050857 DOI: 10.1016/b978-0-12-387718-5.00012-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
There are many challenges associated with the discovery and development of serum-based biomarkers for psychiatric disorders such as schizophrenia. Here, we review these challenges from the point of view of psychiatrists, general practitioners, the regulatory agencies, and biomarker scientists. There is a general opinion in psychiatric medicine that improvements over the current subjective tests are essential. Despite this, there is a reluctance to accept that peripheral molecules can do the job any better. In addition, psychiatrists find it difficult to accept that peripheral molecules, such as those found in blood, can reflect what is happening in the brain. However, the regulatory health authorities now consider biomarkers as important for the future of drug development and have called for efforts to modernize methods, tools, and techniques for the purpose of developing more efficient and safer drugs. We also describe here the development of the first ever molecular blood test for schizophrenia, and its reception in the market place, as a case in point.
Collapse
Affiliation(s)
- Sabine Bahn
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom
| | | | | | | | | |
Collapse
|
20
|
Goodsaid F. Regulatory Perspective for Biomarker Qualification From the U.S. FDA. Biomarkers 2010. [DOI: 10.1002/9780470918562.ch23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
21
|
Hunter DJ, Losina E, Guermazi A, Burstein D, Lassere MN, Kraus V. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr Drug Targets 2010; 11:536-45. [PMID: 20199395 DOI: 10.2174/138945010791011947] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2009] [Accepted: 07/27/2009] [Indexed: 01/12/2023]
Abstract
This narrative review outlines the work done in other fields with regards biomarker validation and qualification and the lessons that we may learn from this experience. Defining a universally agreed upon path for biomarker validation and qualification is urgently needed to circumvent many of the hurdles faced in OA therapeutic development irrespective of whether we are discussing biochemical markers, imaging markers or other measures. This review proposes a path that may be suitable for osteoarthritis and poses some logical next steps that will take us in this direction.
Collapse
Affiliation(s)
- David J Hunter
- Division of Research, New England Baptist Hospital, 125 Parker Hill Ave, Boston MA 02120, USA.
| | | | | | | | | | | |
Collapse
|
22
|
Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. Eur J Cancer 2010; 46:869-79. [PMID: 20138504 DOI: 10.1016/j.ejca.2010.01.001] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2009] [Revised: 12/18/2009] [Accepted: 01/06/2010] [Indexed: 12/26/2022]
Abstract
A priority translational research objective in cancer medicine is the discovery of novel therapeutic targets for solid tumours. Ideally, co-discovery of predictive biomarkers occurs in parallel to facilitate clinical development of agents and ultimately personalise clinical use. However, the identification of clinically useful predictive biomarkers for solid tumours has proven challenging with many initially promising biomarkers failing to translate into clinically useful applications. In particular, the 'failure' of a predictive biomarker has often only become apparent at a relatively late stage in investigation. Recently, the field has recognised the need to develop a robust clinical biomarker development methodology to facilitate the process. This review discusses the recent progress in this area focusing on the key stages in the biomarker development process: discovery, validation, qualification and implementation. Concentrating on predictive biomarkers for selecting systemic therapies for individual patients in the clinic, the advances and progress in each of these stages in biomarker development are outlined and the key remaining challenges are discussed. Specific examples are discussed to illustrate the challenges identified and how they have been addressed. Overall, we find that significant progress has been made towards a formalised biomarker developmental process. This holds considerable promise for facilitating the translation of predictive biomarkers from discovery to clinical implementation. Further enhancements could eventually be found through alignment with regulatory processes.
Collapse
|
23
|
Abstract
Molecular biomarkers are used for various purposes, including disease diagnosis and prognosis, prediction and assessment of treatment response, and safety assessment. There has been a significant increase in the number of US FDA-approved drug labels containing information on molecular biomarkers over the last decade. Almost every pharmaceutical company has been developing molecular biomarker programs, either alone, through partnerships or other ventures. More molecular biomarkers are expected to be identified and validated in drug development, and used to support approval of drug products. This article summarizes the current status of molecular biomarkers used for FDA-approved drug products, and discusses the challenges and future perspectives for the identification and qualification of molecular biomarkers. Specific FDA programs and research projects related to molecular biomarkers are also discussed for supporting regulatory review in the future.
Collapse
Affiliation(s)
- Huixiao Hong
- Center for Toxicoinformatics, Division of Systems Toxicology, National Center for Toxicological Research, US FDA 3900 NCTR Road, Jefferson, AR, USA.
| | | | | | | |
Collapse
|
24
|
Keown PA, McMaster WR, McManus BM. Tools to identify organ rejection and immune quiescence for biological understanding and personalized medical care. Biomark Med 2010; 4:115-21. [PMID: 20387307 DOI: 10.2217/bmm.09.73] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
25
|
Marrer E, Dieterle F. Impact of biomarker development on drug safety assessment. Toxicol Appl Pharmacol 2009; 243:167-79. [PMID: 20036272 DOI: 10.1016/j.taap.2009.12.015] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2009] [Revised: 12/09/2009] [Accepted: 12/10/2009] [Indexed: 02/05/2023]
Abstract
Drug safety has always been a key aspect of drug development. Recently, the Vioxx case and several cases of serious adverse events being linked to high-profile products have increased the importance of drug safety, especially in the eyes of drug development companies and global regulatory agencies. Safety biomarkers are increasingly being seen as helping to provide the clarity, predictability, and certainty needed to gain confidence in decision making: early-stage projects can be stopped quicker, late-stage projects become less risky. Public and private organizations are investing heavily in terms of time, money and manpower on safety biomarker development. An illustrative and "door opening" safety biomarker success story is the recent recognition of kidney safety biomarkers for pre-clinical and limited translational contexts by FDA and EMEA. This milestone achieved for kidney biomarkers and the "know how" acquired is being transferred to other organ toxicities, namely liver, heart, vascular system. New technologies and molecular-based approaches, i.e., molecular pathology as a complement to the classical toolbox, allow promising discoveries in the safety biomarker field. This review will focus on the utility and use of safety biomarkers all along drug development, highlighting the present gaps and opportunities identified in organ toxicity monitoring. A last part will be dedicated to safety biomarker development in general, from identification to diagnostic tests, using the kidney safety biomarkers success as an illustrative example.
Collapse
Affiliation(s)
- Estelle Marrer
- Translational Sciences, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland
| | | |
Collapse
|
26
|
Zhang L, Li H, Benedek D, Li X, Ursano R. A strategy for the development of biomarker tests for PTSD. Med Hypotheses 2009; 73:404-9. [DOI: 10.1016/j.mehy.2009.02.038] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2009] [Revised: 02/09/2009] [Accepted: 02/12/2009] [Indexed: 10/20/2022]
|
27
|
Abstract
Cardiovascular diseases impose enormous social and economic burdens on both individual citizens and on society as a whole. Clinical indicators such as high blood pressure, blood cholesterol and obesity have had some utility in identifying those who are at increased risk of cardiovascular events. However, there remains an urgent need for sensitive and specific indicators, preferably acquired through minimally invasive means, to help stratify patients for more personalized health care. As such, there has been a steadily growing interest in searching for 'omic' biomarkers of cardiovascular diseases. Historically, the transition of cardiac biomarker discovery to implementation has been a lengthy and somewhat unregulated process. Recent technological advancements, as well as concurrent efforts by regulatory agencies such as the Food and Drug Administration (United States) and Health Canada to establish policies and guidelines in the 'omic' arena, have helped propel the discovery and validation of biomarkers forward. The present paper provides perspective on current strategies in the biomarker development pathway, as well as the potential limitations associated with each step from discovery to clinical uptake. Canadian biomarker studies now underway illustrate the possibilities for assessment of risk, diagnosis, prognosis and response to therapy, and for the drug discovery process.
Collapse
Affiliation(s)
- David Lin
- NCE CECR Centre of Excellence for Prevention of Organ Failure
| | | | | | | |
Collapse
|
28
|
Marini F, Brandi ML. Pharmacogenetics of osteoporosis: future perspectives. Calcif Tissue Int 2009; 84:337-47. [PMID: 19271099 DOI: 10.1007/s00223-009-9226-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2008] [Accepted: 02/04/2009] [Indexed: 10/21/2022]
Abstract
Drug response is known to be highly variable among treated patients and affected by many factors, such as age, sex, ethnicity, concomitant diseases, and pharmacological therapy. However, sequence variants in the human genome are now considered an important cause of differences in drug responses. Pharmacogenetics, which is the utilization of individual genetic data to predict the outcome of drug treatment with respect to both beneficial and adverse effects, represents an emerging field of genetics with the potential to become useful for the identification of the most effective drug and the most beneficial dose for a given individual. On the basis of these considerations and thanks to recent advances in genetics and molecular biology, pharmacogenetics is becoming a flowering field in both basic and clinical research. Nevertheless, to date the opportunity to apply pharmacogenetic approaches to drug response and the possibility to use genetic screenings to tailor decisions about pharmacological treatments have limited applications. And this is even truer in the field of osteoporosis, in which pharmacogenetic studies are in their infancy. In this paper we review the most recent data on pharmacogenetics of osteoporosis, highlighting the presentations at the Second International Meeting on Pharmacogenetics of Osteoarticular Disorders held in Florence in April 2008.
Collapse
Affiliation(s)
- Francesca Marini
- Mineral and Bone Metabolism Unit, Department of Internal Medicine, University of Florence, Florence, Italy.
| | | |
Collapse
|
29
|
Baek S, Tsai CA, Chen JJ. Development of biomarker classifiers from high-dimensional data. Brief Bioinform 2009; 10:537-46. [PMID: 19346320 DOI: 10.1093/bib/bbp016] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Recent development of high-throughput technology has accelerated interest in the development of molecular biomarker classifiers for safety assessment, disease diagnostics and prognostics, and prediction of response for patient assignment. This article reviews and evaluates some important aspects and key issues in the development of biomarker classifiers. Development of a biomarker classifier for high-throughput data involves two components: (i) model building and (ii) performance assessment. This article focuses on feature selection in model building and cross validation for performance assessment. A 'frequency' approach to feature selection is presented and compared to the 'conventional' approach in terms of the predictive accuracy and stability of the selected feature set. The two approaches are compared based on four biomarker classifiers, each with a different feature selection method and well-known classification algorithm. In each of the four classifiers the feature predictor set selected by the frequency approach is more stable than the feature set selected by the conventional approach.
Collapse
Affiliation(s)
- Songjoon Baek
- National Center for Toxicological Research, U.S. Food and Drug Administration, USA.
| | | | | |
Collapse
|
30
|
From differentiating metabolites to biomarkers. Anal Bioanal Chem 2009; 394:663-70. [PMID: 19277615 PMCID: PMC2865640 DOI: 10.1007/s00216-009-2690-3] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2008] [Revised: 02/04/2009] [Accepted: 02/06/2009] [Indexed: 01/02/2023]
Abstract
The current developments in metabolomics and metabolic profiling technologies have led to the discovery of several new metabolic biomarkers. Finding metabolites present in significantly different levels between sample sets, however, does not necessarily make these metabolites useful biomarkers. The route to valid and applicable biomarkers (biomarker qualification) is long and demands a significant amount of work. In this overview, we critically discuss the current state-of-the-art of metabolic biomarker discovery, with highlights and shortcomings, and suggest a pathway to clinical usefulness.
Collapse
|
31
|
Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008; 14:5967-76. [PMID: 18829475 DOI: 10.1158/1078-0432.ccr-07-4535] [Citation(s) in RCA: 175] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The role of biomarkers in drug discovery and development has gained precedence over the years. As biomarkers become integrated into drug development and clinical trials, quality assurance and, in particular, assay validation become essential with the need to establish standardized guidelines for analytic methods used in biomarker measurements. New biomarkers can revolutionize both the development and use of therapeutics but are contingent on the establishment of a concrete validation process that addresses technology integration and method validation as well as regulatory pathways for efficient biomarker development. This perspective focuses on the general principles of the biomarker validation process with an emphasis on assay validation and the collaborative efforts undertaken by various sectors to promote the standardization of this procedure for efficient biomarker development.
Collapse
Affiliation(s)
- Cindy H Chau
- Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
| | | | | | | |
Collapse
|
32
|
Huang SM, Kim MJ, Goodsaid F, Frueh F, Lesko L. Application of Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Review. Genomics 2008. [DOI: 10.3109/9781420067064-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
33
|
Cattaneo D, Baldelli S, Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am J Transplant 2008; 8:1374-83. [PMID: 18510642 DOI: 10.1111/j.1600-6143.2008.02263.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Most of the immunosuppressants used in organ transplantation are characterized by a narrow therapeutic index, whereby underdosing is associated with increased risk of rejection episodes and overdosing may exacerbate drug-related toxicity. Pharmacogenetics--complementary to pharmacokinetics--holds the potential to allow individualized dosing of immunosuppressive agents to optimize their therapeutic actions while minimizing adverse effects. Most of the studies have focused on polymorphisms of genes involved in drug metabolism and distribution, but as of now, only thiopurine-S-methyltransferase and cytochrome P 450 3A5 genotypes appear to have sufficiently large influence to have potentialities in guiding drug dosing. This may reflect the fact that available information from other polymorphisms derives almost exclusively from retrospective observations or from studies with important methodological biases. Active investigations aimed at identifying allelic variants of gene encoding for the pharmacologic targets are now ongoing. Recent studies have demonstrated that also donor genotype may play a significant role in immunosuppressive drug pharmacokinetics and pharmacodynamics. As one of the main future tasks, it is mandatory to develop mathematical models able to incorporate multiple gene polymorphisms with pharmacokinetic data and other critical information, providing algorithms able to individualize the best immunosuppressive therapy for each patient before transplantation.
Collapse
Affiliation(s)
- D Cattaneo
- Department of Medicine and Transplantation, Azienda Ospedaliera Ospedali Riuniti, Bergamo and Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
| | | | | |
Collapse
|
34
|
Mendrick DL. Genomic and genetic biomarkers of toxicity. Toxicology 2008; 245:175-81. [DOI: 10.1016/j.tox.2007.11.013] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2007] [Accepted: 11/20/2007] [Indexed: 11/28/2022]
|
35
|
Burckart GJ, Amur S, Goodsaid FM, Lesko LJ, Frueh FW, Huang SM, Cavaille-Coll MW. Qualification of biomarkers for drug development in organ transplantation. Am J Transplant 2008; 8:267-70. [PMID: 18093264 DOI: 10.1111/j.1600-6143.2007.02063.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The drug development process is dependent upon having established end points for measuring drug efficacy and adverse effects. New drug development in organ transplantation suffers from having end points which are either outdated or which do not serve the purpose of addressing the current critical drug therapy problems. Numerous biomarkers have been examined in organ transplantation, but almost all would be classified as exploratory for drug development purposes. Some of the possible pathways out of this dilemma include investigator- or consortium-initiated research that would qualify the biomarkers as either probable or known valid biomarkers, help in identification of new end points in transplantation and their associated biomarkers, co-development of a new biomarker and drug for transplantation and the use of new clinical trial design methods which facilitate enriched or stratified transplant patient populations. With new biomarkers and new study design methodologies for drug development, improvement in the drug development process for transplantation is a real possibility that the transplant clinical and research community can help to bring about.
Collapse
Affiliation(s)
- Gilbert J Burckart
- School of Pharmacy, University of Southern California, Los Angeles, CA, USA.
| | | | | | | | | | | | | |
Collapse
|
36
|
Goodsaid FM, Frueh FW, Mattes W. Strategic paths for biomarker qualification. Toxicology 2008; 245:219-23. [PMID: 18280028 DOI: 10.1016/j.tox.2007.12.023] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2007] [Accepted: 12/17/2007] [Indexed: 11/25/2022]
Abstract
Biomarkers may be qualified using different qualification processes. A passive approach for qualification has been to accept the end of discussions in the scientific literature as an indication that a biomarker has been accepted. An active approach to qualification requires development of a comprehensive process by which a consensus may be reached about the qualification of a biomarker. Active strategies for qualification include those associated with context-independent as well as context-dependent qualifications.
Collapse
Affiliation(s)
- Federico M Goodsaid
- Genomics Group, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, FDA, MD 20903-0002, United States.
| | | | | |
Collapse
|
37
|
Abstract
There is a need for new biomarkers to enable faster detection of adverse events due to drugs and disease processes. One would prefer biomarkers that are useful in multiple species (i.e., translational or bridging biomarkers) so that it would be possible to directly link responses between species and follow such injury in both preclinical and clinical settings. This chapter will explore some of the issues surrounding the use of pharmacogenomics to identify and qualify such biomarkers, and examples will be provided.
Collapse
Affiliation(s)
- Donna L Mendrick
- Department of Toxicogenomics, Gene Logic Inc., Gaithersburg, Maryland, USA
| |
Collapse
|
38
|
Applications of toxicogenomics to nonclinical drug development: regulatory science considerations. Methods Mol Biol 2008; 460:239-61. [PMID: 18449491 DOI: 10.1007/978-1-60327-048-9_12] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Scientists in the pharmaceutical industry have ready access to samples from animal toxicology studies carefully designed to test the safety characteristics of a steady pipeline of agents advancing toward clinical testing. Applications of toxicogenomics to the evaluation of compounds could best be realized if this promising technology could be implemented in these studies fully anchored in the traditional study end points currently used to characterize phenotypic outcome and to support the safe conduct of clinical testing. Regulatory authorities worldwide have declared their support for toxicogenomics and related technological tools to positively impact drug development, and guidance has been published. However, applications of exploratory "omics" technologies to compounds undergoing safety testing remain inhibited due to two core data submission responsibility implications and ambiguities: (1) constraints arising from continual literature surveillance and data reanalysis burdens, under the shadow of looming subsequent reporting requirements to regulatory authorities as gene expression end points loosely linked to safety gain attention in the published literature, and (2) ambiguities in interpretation of validation stature remain between exploratory, probable valid, and known valid safety biomarkers. A proposal is offered to address these regulatory implementation barriers to open access for exploring this technology in prospective drug development animal toxicology studies.
Collapse
|
39
|
Mendrick DL. Toxicogenomics and classic toxicology: how to improve prediction and mechanistic understanding of human toxicity. Methods Mol Biol 2008; 460:1-22. [PMID: 18449480 DOI: 10.1007/978-1-60327-048-9_1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The field of toxicogenomics has been advancing during the past decade or so since its origin. Most pharmaceutical companies are using it in one or more ways to improve their productivity and supplement their classic toxicology studies. Acceptance of toxicogenomics will continue to grow as regulatory concerns are addressed, proof of concept studies are disseminated more fully, and internal case studies show value for the use of this new technology in concert with classic testing.
Collapse
Affiliation(s)
- Donna L Mendrick
- Department of Toxicogenomics, Gene Logic Inc., Gaithersburg, Maryland, USA
| |
Collapse
|
40
|
Isler JA, Vesterqvist OE, Burczynski ME. Analytical validation of genotyping assays in the biomarker laboratory. Pharmacogenomics 2007; 8:353-68. [PMID: 17391073 DOI: 10.2217/14622416.8.4.353] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
High-throughput, whole-genome association studies conducted in various diseases and therapeutic settings are identifying an increasing number of single nucleotide polymorphisms that may predict patient responses and ultimately guide therapeutic decision-making. In order to confirm the candidate genetic markers emerging from these studies, there is a commensurate need for pharmacogenomic laboratories to design and analytically validate targeted genotyping assays capable of rapidly querying the identified individual single nucleotide polymorphisms of interest in large confirmatory clinical studies. In recent years, a number of increasingly complex technologies have been applied to the qualitative and semi-quantitative analysis of polymorphisms and mutations in DNA. The different approaches available for targeted DNA sequence analysis are characterized by various pros and cons that often present technology-specific challenges to the analytical validation of these assays prior to their use in clinical studies. Several key principles in the analytical validation of genotyping assays--including assay specificity, sensitivity, reproducibility and accuracy--are covered in this review article, with specific attention paid to three major end point detection technologies currently employed in targeted genotyping analysis: matrix-assisted laser desorption ionization time-of-flight mass spectrometry, Pyrosequencing and Taqman-based allelic discrimination. Thorough assessment of the performance of genotyping assays during analytical validation, and careful use of quality controls during sample analysis, will help strengthen the quality of pharmacogenomic data used to ultimately confirm the validity of exploratory biomarkers in DNA.
Collapse
Affiliation(s)
- Jennifer A Isler
- Wyeth Research, Biomarker Laboratory, Clinical Translational Medicine, 500 Arcola Road, Collegeville, PA 19426, USA
| | | | | |
Collapse
|
41
|
Hardouin J, Lasserre JP, Sylvius L, Joubert-Caron R, Caron M. Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann N Y Acad Sci 2007; 1107:223-30. [PMID: 17804550 DOI: 10.1196/annals.1381.024] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Cancer remains one of the leading causes of death worldwide. Thus, to identify any useful biomarkers is still a need. We performed "cancer immunomics" to identify autoantibody signatures produced in response to the presence of either breast or colorectal cancer. SERological proteome analysis (SERPA) was performed by two-dimensional (2-D) electrophoresis separation, immunoblotting, image analysis, and mass spectrometry. Alternatively, to identify the antigens recognized by the autoantibodies of cancer patients, we developed an approach combining 2-D immunoaffinity chromatography, enzymatic digestion of the isolated antigens, nano flow separation of the resulting peptides, and identification: MAPPing (multiple affinity protein profiling). By these approaches we identified both proteins recognized by autoantibodies independently of a cancer status, and a limited number of proteins reacting preferentially with cancer sera.
Collapse
Affiliation(s)
- Julie Hardouin
- Protein Biochemistry and Proteomics Laboratory, CNRS UMR 7033 (BioMoCeti), UFR SMBH Leonard de Vinci, University Paris13, 74, rue Marcel Cachin, 93017 Bobigny cedex, France
| | | | | | | | | |
Collapse
|
42
|
Mendrick DL, Daniels KK. From the bench to the clinic and back again: translational biomarker discovery using in silico mining of pharmacogenomic data. Biomark Med 2007; 1:319-33. [PMID: 20477406 DOI: 10.2217/17520363.1.2.319] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
To improve drug efficacy and safety and advance medical intervention in diseases, new biomarkers are urgently needed. Pharmacogenomics can provide a tool to discover and begin to qualify biomarkers useful for these indications and is readily applicable to multiple species. One can begin and end with genes or focus on tissue-derived expression analysis of those genes that encode secreted proteins to discover potential biomarkers that can be monitored in body fluids. The paper will discuss issues surrounding such investigations, show examples of translational biomarkers and end with a summary of the US FDA’s work in this field over the last 6 years.
Collapse
Affiliation(s)
- Donna L Mendrick
- Gene Logic Inc., 50 West Watkins Mill Road, Gaithersburg, MA 20878, USA
| | - Kellye K Daniels
- Gene Logic Inc., 50 West Watkins Mill Road, Gaithersburg, MA 20878, USA
| |
Collapse
|
43
|
Abstract
Biomarkers have been a buzz word in drug development for the last 5 years. But where do we stand now? This perspective article will demonstrate to which extent biomarkers have impacted drug development and the use of drugs. In particular, the different types of biomarkers, their identification, validation and use in different phases of drug development from drug discovery, to approval, to clinical application will be discussed as well as the state-of-the-art biomarker technologies and promising future methods. The high interest in biomarkers has generated the need for development of new technologies and refinement of existing ones. Besides discussing their perspectives of applications, the present article also illustrates the future of biomarker development in terms of qualification for regulatory use and co-development.
Collapse
Affiliation(s)
- Estelle Marrer
- Novartis Pharma AG, Development, 4002 Basel, Switzerland.
| | | |
Collapse
|
44
|
Goodsaid F, Frueh FW. Implementing the U.S. FDA guidance on pharmacogenomic data submissions. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2007; 48:354-8. [PMID: 17567848 DOI: 10.1002/em.20294] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
The FDA Guidance for Industry: Pharmacogenomics Data Submissions was issued in 2005. This guidance document covers a broad area associated with how and when to submit genomic data to the FDA. Additional tasks associated with genomic data submissions include the implementation of genomic data submissions; the process for qualification of exploratory biomarkers into valid biomarkers; and technical recommendations for the generation and submission of genomic data to the FDA. These tasks have been addressed throughout the past 2 years by a number of initiatives. These initiatives have included the development of the Interdisciplinary Pharmacogenomics Review Group for review of pharmacogenomic data submissions, the pilot process for qualification of biomarkers, and the concept paper on recommendations for the generation and submission of genomic data. These initiatives have contributed to the effective implementation of the Pharmacogenomics Guidance at the FDA.
Collapse
Affiliation(s)
- Federico Goodsaid
- Genomics Group, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903-0002, USA.
| | | |
Collapse
|
45
|
Dunnick JK, Thayer KA, Travlos GS. Inclusion of biomarkers for detecting perturbations in the heart and lung and lipid/carbohydrate metabolism in National Toxicology Program studies. Toxicol Sci 2007; 100:29-35. [PMID: 17490986 PMCID: PMC2080693 DOI: 10.1093/toxsci/kfm113] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Environmental factors and exposures may contribute to many serious diseases afflicting humans. Biomarkers are useful to understand disease processes and identify early events leading to disease. The National Toxicology Program (NTP) convened a workshop in September 2006 to help identify biomarkers that could be used in toxicology studies with rodents to predict disease outcome and detect early events in disease processes. Expert scientists reviewed biomarkers for disease/injury related to the heart, lung, and/or changes in lipid/carbohydrate metabolism and made recommendations for those that could be incorporated into NTP studies on a routine or selective basis. Although numerous biomarkers were discussed, only a few were considered amenable for routine use. This article summarizes recommendations for the most promising biomarkers and presents the NTP perspective on those that will be included in the bioassay program on a routine or special study basis. Breakout group reports and additional information on the workshop, including participants, presentations, and background materials, are posted on the NTP Web site http://ntp.niehs.nih.gov/go/20940.
Collapse
Affiliation(s)
- June K Dunnick
- National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA.
| | | | | |
Collapse
|
46
|
Orr MS, Goodsaid F, Amur S, Rudman A, Frueh FW. The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program. Clin Pharmacol Ther 2007; 81:294-7. [PMID: 17259954 DOI: 10.1038/sj.clpt.6100053] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Drug developers have been using genomic information in drug development strategies for a number of years, but it was unclear how this information would be reviewed by the Food and Drug Administration (FDA). In order to evaluate the regulatory impact of genomic data in current drug development, a workshop was held in May 2002 to discuss aspects surrounding genomic data submission to the FDA (Figure 1).
Collapse
Affiliation(s)
- M S Orr
- Genomics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
| | | | | | | | | |
Collapse
|
47
|
Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS JOURNAL 2007; 9:E105-8. [PMID: 17408233 PMCID: PMC2751298 DOI: 10.1208/aapsj0901010] [Citation(s) in RCA: 125] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
New biomarkers of safety and efficacy are becoming powerful tools in drug development. Their application can be accelerated if a consensus can be reached about their qualification for regulatory applications. This consensus requires a review structure within the US Food and Drug Administration (FDA) that can evaluate qualification data for these biomarkers and determine whether these biomarkers can be qualified. A pilot process and corresponding Biomarker Qualification Review Team have been developed to test how the FDA can work on biomarker qualification.
Collapse
Affiliation(s)
- Federico Goodsaid
- Genomics Group, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903-0002, USA.
| | | |
Collapse
|
48
|
Goodsaid FM, Frueh FW. Questions and answers about the Pilot Process for Biomarker Qualification at the FDA. DRUG DISCOVERY TODAY. TECHNOLOGIES 2007; 4:9-11. [PMID: 24980714 DOI: 10.1016/j.ddtec.2007.10.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The FDA has developed a Pilot Process for Biomarker Qualification. Initial experience with this process has underscored the care that a long-term approach to biomarker qualification independently of development for specific drugs should have in the assembly of external industry consortia as well as the internal regulatory organization for these qualification efforts. There are complex scientific and clinical issues associated with these qualifications, and it is paramount that the expertise needed for their review be identified so that a comprehensive consensus may be reached at the end of this process. Several frequently asked questions associated with this process are presented in this paper, as well as answers reflecting the Agency's current thinking about this process.:
Collapse
Affiliation(s)
- Federico M Goodsaid
- Genomics Group, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA.
| | - Felix W Frueh
- Genomics Group, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA
| |
Collapse
|